atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

Articles | March 3, 2021

atai Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and… Read More

atai Life Sciences’ Perception Neuroscience’s PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study

Articles | February 19, 2021

Perception Neuroscience, an atai Life Sciences biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine that is being developed for therapeutic treatment of psychiatric… Read More

atai Life Sciences’ EmpathBio announces joint feasibility assessment of Bionomics’ BNC210 and EmpathBio’s MDMA derivative EMP-01 treatment regimen for PTSD

Articles | February 17, 2021

Bionomics Limited today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences. Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics’ BNC210 and EmpathBio’s… Read More